Nanotechnology based platforms for survivin targeted drug discovery

Expert Opinion on Drug Discovery

Volumn 7, Issue 11, 2012, Pages 1083-1092

  Samarasinghe, Rasika M ^a   Gibbons, Jessica ^a   Kanwar, Rupinder K ^a   Kanwar, Jagat R ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Cancer; Liposomes; Nanotherapy; Polymeric; Survivin

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGONUCLEOTIDE; C84A PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CHAPERONIN 60; CISPLATIN; D53A PROTEIN; DENDRIMER; GATAPARSEN; HEAT SHOCK PROTEIN 90; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MSURVIVIN T34A; MYC PROTEIN; NANOMATERIAL; PLASMID VECTOR; PROTEIN MDM2; SMALL INTERFERING RNA; SPC 3042; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SURVIVIN; T34A C84A PROTEIN; T34A PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CELL DEATH; CELL DIVISION; CELL PROTECTION; CHEMOSENSITIZATION; COMPUTER ASSISTED TOMOGRAPHY; DNA CROSS LINKING; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LARYNX SQUAMOUS CELL CARCINOMA; LEWIS CARCINOMA; LIPOSOMAL DELIVERY; LUNG METASTASIS; NANOMEDICINE; NEAR INFRARED SPECTROSCOPY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NANOTECHNOLOGY; NEOPLASMS;

EID: 84867957622     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.719869     Document Type: Review

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326(Pt 1):1-16 (Pubitemid 27386911)
3. Altieri DC. Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 2003;3:46-54 (Pubitemid 37328886)
4. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5
5. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007;27:17-28 (Pubitemid 46991388)
6. Altieri DC. Targeting survivin in cancer. Cancer Lett 2012. [Epub ahead of print]
7. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011;16:485-94
8. Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin signaling in clinical oncology: A multifaceted dragon. Med Res Rev 2012. [Epub ahead of print]
9. Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010;16:6150-8
10. Trepiakas R, Berntsen A, Hadrup SR, et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 2010;12:721-34
11. Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008;31:771-80
12. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature 1997;389:239-42
13. Kanwar JR, Shen WP, Kanwar RK, et al. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-52 (Pubitemid 32998483)
14. Baratchi S, Kanwar RK, Cheung CH, et al. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol 2010;227:120-32
15. Baratchi S, Kanwar RK, Kanwar JR. Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. J Neuroimmunol 2011;233:18-28
16. Baratchi S, Kanwar RK, Kanwar JR. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS ONE 2011;6:e15865
17. Cheung CH, Sun X, Kanwar JR, et al. A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell Int 2010;10:36
18. Grossman D, Kim PJ, Schechner JS, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001;98:635-40 (Pubitemid 32105095)
19. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000;97:13103-7
20. Peng XC, Yang L, Yang LP, et al. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-Ala mutant. J Exp Clin Cancer Res 2008;27:46
21. Shan Y, Wang C, Yang L, et al. Inhibition of human lung adenocarcinoma growth using survivint34a by low-dose systematic administration. J Biosci 2010;35:209-16
22. Pan L, Peng XC, Leng F, et al. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer. J Cancer Res Clin Oncol 2011;137:19-28
23. Yu DD, Wang CT, Shi HS, et al. Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant. J Exp Clin Cancer Res 2010;29:46
24. Seth S, Matsui Y, Fosnaugh K, et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther 2011;19:928-35
25. Kenny GD, Kamaly N, Kalber TL, et al. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release 2011;149:111-16
26. Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650-6
27. Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol 2012. [Epub ahead of print]
28. Liu X, Ryland L, Yang J, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010;116:4192-201
29. Jatzkewitz H. Incorporation of physiologically-active substances into a colloidal blood plasma substitute. I. Incorporation of mescaline peptide into polyvinylpyrrolidone. Hoppe Seylers Z Physiol Chem 1954;297:149-56
30. Zhang L, Gao X, Men K, et al. Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticlemediated survivin T34A. Int J Nanomedicine 2011;6:2419-27
31. Yan Y, Jiang J, Cao M, et al. Survivin antisense oligodeoxynucleotide mediated by polyethyleneimine enhances sensitivity to chemotherapy in SMMC-7721,a human hepatocelluar carcinoma cell line. J Jinan Univ 2007;28:147-51
32. Wu F, Huang G, Jiang J, et al. Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu. J S Med Univ 2009;29:2251-4
33. Bhattacharyya SS, Paul S, and Khuda-Bukhsh AR Encapsulated plant extract (Gelsemium sempervirens) poly (lactide-co-glycolide) nanoparticles enhance cellular uptake and increase bioactivity in vitro. Exp Biol Med (Maywood) 2010;235:678-88
34. Paul S, Bhattacharyya SS, Boujedaini N, et al. Anticancer Potentials of Root Extract of Polygala senega and Its PLGA Nanoparticles-Encapsulated Form. Evid Based Complement Alternat Med 2011;2011: Article ID 517204
35. Liu S, Sun X, Nie Y, et al. Preparation and characteristics of chitosan nanoparticles carrying gene in vitro. West China J Pharm Sci 2004;19:409-11
36. Yu L, Zhang Y, Song C, et al. Preparation and characterization of PEGylated chitosan/survivin siRNA complex. China J Mod Med 2009;19:1130-33
37. Kanwar JR, Mahidhara G, and Kanwar RK Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov Today 2011;16:188-202
38. Wang Y, Han Y, Yang Y, et al. Effect of interaction of magnetic nanoparticles of Fe3O4 and artesunate on apoptosis of K562 cells. Int J Nanomed 2011;6:1185-92
39. Wang J, Chen B, Cheng J, et al. Apoptotic mechanism of human leukemia K562/A02 cells induced by magnetic iron oxide nanoparticles co-loaded with daunorubicin and 5-bromotetrandrin. Int J Nanomed 2011;6:1027-34
40. Cao Z, Sun Y, Zhu Y, et al. Construction of magnetic small interfering RNA nanoparticles and effects of its transfection on silencing survivin gene expression and inducing human bladder cancer cell apoptosis. China J Mod Med 2008;18:385-90
41. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007;13:372-7 (Pubitemid 46376679)
42. Peng J, He X, Wang K, et al. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells. Nanomedicine 2006;2:113-20 (Pubitemid 43956609)
43. Medina SH, El-Sayed MEH. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 2009;109:3141-57
44. Yao H, Yue S, Jin Y, et al. Construction of survivin antisense oligodeoxynucleotide polyamidoamine carrier and its influence on apoptosis of hepatic cancer cells. Chin J Cancer Biother 2007;14:540-44
45. Yao H, YUE S, Jin Y, et al. Anti-tumor and anti-angiogenesis effects of survivin antisense oligodeoxynucleo-tide delivered by polyamidoamine dendrimer on subcutaneously-transplanted hepatic cancer in nude mice. Chin J Cancer Biother 2008;15:36-40 (Pubitemid 351384987)
46. Li Z, Huang Z, Cui D, et al. Polyamidoamine dendrimer-mediated survivin antisense oligonucleotide inhibits the growth of subcutaneously transplanted colorectal cancer in nude mice. J South Med Univ 2008;28:1935-8
47. Liu X, Huang H, Wang J, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 2011;82:17-23
48. Pan B, Cui D, Sheng Y, et al. Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system. Cancer Res 2007;67:8156-63 (Pubitemid 47395151)
49. Nel A, Xia T, Madler L, et al. Toxic potential of materials at the nanolevel. Science 2006;311:622-7 (Pubitemid 43191298)
50. Arora S, Rajwade JM, Paknikar KM. Nanotoxicology and in vitro studies: the need of the hour. Toxicol Appl Pharmacol 2012;258:151-65